Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While AOD-9604 is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials71111115, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While AOD-9604 works as a synthetic fragment of human growth hormone corresponding to residues 176–191 with an added N-terminal tyrosine, retaining lipolytic but not growth-promoting actions; proposed to stimulate lipolysis and inhibit lipogenesis in adipose tissue, partly via β3-adrenergic pathways without significantly activating the full GH receptor–IGF-1 axis6171111, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
AOD-9604
GH1
Liraglutide
GCG
Both peptides fall into a similar broad context as Metabolic peptide and Hormone peptide, although the details of how they are used and discussed still diverge. Both are most often discussed in Metabolic and endocrine, which gives the comparison a meaningful common setting even when the rest of their profiles are not identical. Both appear to work through Hormone analog, but the functional emphasis still separates, with AOD-9604 leaning toward Lipolysis and fat loss and Liraglutide leaning toward Metabolic regulation. Both are synthetic in origin and their development context also differs, with AOD-9604 in Preclinical development while Liraglutide is approved. AOD-9604 takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, Liraglutide incorporates palmitoylation features that are not part of AOD-9604; while their sequence patterns also diverge, with AOD-9604 showing hydrophobic domain features and Liraglutide showing alpha-helical domain features.